Delving into the Latest Updates on Recombinant humanized anti-IL17A monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

重组人源化抗IL17A单克隆抗体 (上海三生国健)

Target

IL-17A

Action

inhibitors

Mechanism

IL-17A inhibitors(Interleukin 17A inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesInfectious Diseases

Active Indication

Plaque psoriasisChronic large plaque psoriasisNon-radiographic axial spondyloarthritis+ [2]

Inactive Indication-

Originator Organization-

Active Organization

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

3SBio, Inc.

Inactive Organization-

Drug Highest PhaseNDA/BLA

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDAdipose tissue is infiltrated with various immune cells, including Th17 lymphocytes and monocytes/macrophages, in obese individuals. We have previously demonstrated the role of obese adipose-derived stem cells (ob-ASC) and adipocytes (AD) in the mediation of inflammation through promotion of Th17 cells and activation of monocytes. Such an inflammation resulted in impaired ob-ASC adipogenesis and AD insulin response. In the present study, we investigated the role of IL-17A in the impairment of these functions.METHODSWith this aim, we used Secukinumab, a potent human anti-IL17A monoclonal antibody which has been approved for the treatment of some IL-17A related inflammatory diseases, notably Psoriasis. This antibody was added or not to phytohemagglutinin A-activated co-cultures of ob-ASC and mononuclear cells. The conditioning media of those co-cultures were harvested and added to AD ongoing differentiation from ob-ASC. Adipogenesis, insulin sensitivity and secretion of inflammatory cytokines were then measured using qRT-PCR, Western blots and ELISAs, respectively.RESULTSSurprisingly, we did not observe any direct effect of IL-17A on ob-ASC adipogenesis, despite sensitivity of ob-ASC to IL-17A. Moreover, IL-17A blockade, with the help of Secukinumab, did not lead to the recovery of adipogenesis and insulin response, when these functions were impaired by the presence of an inflammatory conditioning medium. However, the up-regulation of IL6 and IL1B mRNA expression by AD submitted to inflammatory conditioning medium was inhibited in the presence of Secukinumab, which indicates that IL-17A may play a role in the propagation of inflammation towards AD.IN CONCLUSIONwe show herein that IL-17A does not play a major role in the impairment of adipogenesis and/or insulin resistance mediated by an inflammatory environment, but contributes to the propagation of inflammation in human obese adipose tissues. This suggests a beneficial effect of anti-IL17A mAb in inflammatory pathologies, where obesity contributes to poorer response to biologic treatments.

01 May 2019·Journal of Cellular BiochemistryQ3 · BIOLOGY

A three microRNA‐based prognostic signature for small cell lung cancer overall survival

Q3 · BIOLOGY

Article

Author: Liu, Jindong ; Ma, Jing ; Xin, Shaobin ; Zhang, Heng ; Yan, Hao ; Wang, Hui

AbstractBackgroundSmall‐cell lung cancer (SCLC) is one of the most aggressive cancers with mechanisms far from understood.ObjectiveWe proposed to identify valuable prognostic signature for SCLC prognosis prediction.MethodsmicroRNA (miRNA) expression profiles of 42 SCLC patients were acquired from the Gene Expression Omnibus. miRNAs that significantly associated with SCLC overall survival (OS‐relevant) were identified through univariate Cox regression analysis followed by random survival forest analysis for identification of more reliable miRNA signature.ResultsEleven OS‐relevant miRNAs were obtained, and hsa‐miR‐194, hsa‐miR‐608, and hsa‐miR‐9 were further refined through RFS. A formula composed of the three miRNAs’ expression values weighted by their multivariate Cox regression coefficients was constructed, and based on which, SCLC patients with longer OS could be well distinguished from those with shorter OS.ConclusionsThis study should provide a valuable clue for SCLC prognosis evaluation.

01 Dec 2017·Molecular CancerQ1 · MEDICINE

MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway

Q1 · MEDICINE

ArticleOA

Author: Hu, Zhenghui ; Zhu, Yi ; Lin, Yiwei ; Wang, Xiao ; Liang, Zhen ; Ji, Alin ; Liu, Ben ; Li, Shiqi ; Meng, Shuai ; Wu, Jian ; Xie, Liping ; Xie, Bo ; Zheng, Xiangyi ; Xu, Xin

BACKGROUNDCurrent evidence indicates that miR-608 is widely down-regulated in various malignant tumors including liver cancer, colon cancer, lung cancer and glioma, and acts as a tumor suppressor by inhibiting cell proliferation, invasion and migration or by promoting apoptosis. The specific biological function of miR-608 in bladder cancer is still unknown.METHODSqRT-PCR and Chromogenic in Situ Hybridization (CISH) was conducted to assess the expression of miR-608 in paired BCa tissues and adjacent non-tumor bladder urothelial tissues. Bisulfite sequencing PCR was used for DNA methylation analysis. CCK-8, colony formation and flow cytometry assays were performed, and a xenograft model was studied. Immunohistochemistry staining was performed with peroxidase and DAB. The target of miR-608 was validated with a dual-luciferase reporter assay, quantitative RT-PCR, and Western blotting.RESULTSmiR-608 is frequently down-regulated in human BCa tissues. The methylation status of CpG islands is involved in the regulation of miR-608 expression. Overexpression of miR-608 inhibits the proliferation and tumorigenesis of BCa cells in vitro and in vivo. Additionally, up-regulation of miR-608 in BCa cells induces G1-phase arrest through AKT/FOXO3a signaling. In contrast, down-regulation of miR-608 promotes proliferation and cell cycle progression in BCa cells. Moreover, the expression of FLOT1 was directly inhibited by miR-608, the down-regulation of FLOT1 induced by siFLOT1 could be significantly reversed by miR-608 inhibitor. Similarly, the up-regulation of FLOT1 by FLOT1 overexpression plasmid (pFLOT1) could also reverse the suppressed cell proliferation caused by miR-608.CONCLUSIONSmiR-608 is a potential tumor suppressor in BCa, and the restoration of miR-608 might be a promising therapeutic option for BCa.

100 Deals associated with Recombinant humanized anti-IL17A monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	NDA/BLA	China	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	19 Nov 2024
Chronic large plaque psoriasis	Phase 3	China	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	07 Jan 2023
Non-radiographic axial spondyloarthritis	Phase 2	China	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	18 Mar 2024
Ankylosing Spondylitis	Phase 2	China	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	27 Feb 2024
Autoimmune Diseases	Phase 2	China	3SBio, Inc.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05536726 (NEWS) Manual	Phase 3	Plaque psoriasis	-	608：160 mg W0+80 mg Q2W+80mg Q4W	(ocqarwljoz) = lgmnzjzhxh jyfjaqnjnv (aighdhsxdv ) Met View more	Positive	02 Aug 2024
				608：160 mg Q4W+160mg Q8W	(ocqarwljoz) = vzrrdhjwmh jyfjaqnjnv (aighdhsxdv ) Met View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data